MX2009006889A - Compounds with a combination of cannabinoid-cb1 antagonism and acetylcholinesterase inhibition. - Google Patents

Compounds with a combination of cannabinoid-cb1 antagonism and acetylcholinesterase inhibition.

Info

Publication number
MX2009006889A
MX2009006889A MX2009006889A MX2009006889A MX2009006889A MX 2009006889 A MX2009006889 A MX 2009006889A MX 2009006889 A MX2009006889 A MX 2009006889A MX 2009006889 A MX2009006889 A MX 2009006889A MX 2009006889 A MX2009006889 A MX 2009006889A
Authority
MX
Mexico
Prior art keywords
compounds
methods
cannabinoid
combination
preparing
Prior art date
Application number
MX2009006889A
Other languages
Spanish (es)
Inventor
Cornelis G Kruse
Josephus H M Lange
Belal Shadid
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Priority claimed from PCT/EP2007/064169 external-priority patent/WO2008074816A1/en
Publication of MX2009006889A publication Critical patent/MX2009006889A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Thisinvention concerns compounds with a combination of cannabinoid-CB1antagonism and cholinesterase inhibition, to pharmaceutical compositions containing these compounds, to methods for preparing the compounds, methods for preparing novel intermediates useful for their synthesis, and methods for preparing compositions. The invention also relates to the uses of such compounds and compositions, particularly for treating Alzheimer's disease, cognitive disorders, memory disorders, dementia, attention deficits, traumatic brain injury, drug dependence, addiction and substance abuse. In particular the invention relates to compounds of the general Formula (1) wherein the symbols have the meanings given in the specification.
MX2009006889A 2006-12-20 2007-12-19 Compounds with a combination of cannabinoid-cb1 antagonism and acetylcholinesterase inhibition. MX2009006889A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06126584 2006-12-20
PCT/EP2007/064169 WO2008074816A1 (en) 2006-12-20 2007-12-19 Compounds with a combination of cannabinoid-cb1 antagonism and acetylcholinesterase inhibition

Publications (1)

Publication Number Publication Date
MX2009006889A true MX2009006889A (en) 2009-07-07

Family

ID=38024247

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006889A MX2009006889A (en) 2006-12-20 2007-12-19 Compounds with a combination of cannabinoid-cb1 antagonism and acetylcholinesterase inhibition.

Country Status (7)

Country Link
CN (1) CN101848907A (en)
AR (1) AR064379A1 (en)
BR (1) BRPI0721060A2 (en)
IN (1) IN2009CN03566A (en)
MX (1) MX2009006889A (en)
TW (1) TW200843772A (en)
ZA (1) ZA200903779B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4183264A1 (en) * 2020-07-14 2023-05-24 Liscure Biosciences Co., Ltd. Composition for treating brain disease comprising pediococcus inopinatus or extracellular vesicles derived therefrom as active ingredient
WO2022089598A1 (en) * 2020-10-30 2022-05-05 杭州拉林智能科技有限公司 Flavonoid glycoside-organic amine neuroagonist double salt compound, preparation method therefor, and application thereof

Also Published As

Publication number Publication date
TW200843772A (en) 2008-11-16
CN101848907A (en) 2010-09-29
BRPI0721060A2 (en) 2014-02-25
AR064379A1 (en) 2009-04-01
ZA200903779B (en) 2010-04-28
IN2009CN03566A (en) 2015-08-07

Similar Documents

Publication Publication Date Title
IL198926A0 (en) Compounds with a combination of cannabinoid-cb1 antagonism and acetylcholinesterase inhibition
TW200633957A (en) Compounds
UA94660C2 (en) Amino-heterocyclic compounds
JO3146B1 (en) Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders
RS20060129A (en) /1,8/naphthyridin-2-ones and related compounds for the treatment of schizophrenia
TW200531689A (en) Therapeutic agents
MXPA06011194A (en) Thiadiazolidinones as gsk-3 inhibitors.
ATE455763T1 (en) PIPERIDINE AND RELATED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
IL176546A0 (en) Imidazoline derivatives having cb1-antagonistic activity
PH12013502376B1 (en) Arylsulfonyl pyrazoline carboxamidine derivatives as 5-ht6 antagonists
UA100232C2 (en) Crystalline forms glyt1
WO2010018213A3 (en) Spiroimidazole compounds suitable for the treatment of neurological disorders
MY136718A (en) Sulfonamide compounds for the treatment of neurodegenerative disorders
EP2416795A4 (en) Inhibitors of cognitive decline
MX2009005509A (en) 2-aminoquinolines as 5-ht(5a) receptor antagonists.
TW200633956A (en) Compounds
PT1745010E (en) Substituted cyclohexyl-1,4-diamine derivatives
TW200714282A (en) Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia
WO2005095348A3 (en) Pyrazole-amine compounds for the treatment of neurodegenerative disorders
MX2009006889A (en) Compounds with a combination of cannabinoid-cb1 antagonism and acetylcholinesterase inhibition.
RS20080139A (en) Imidazole coumpounds for the treatment of neurological disorders
GB0428232D0 (en) Compounds
WO2008102888A1 (en) Novel pseudoglycolipid and use thereof
MX2009007405A (en) Compounds with a combination of cannabinoid-cb1 antagonism and serotonin reuptake inhibition.
MX2010008239A (en) 2-aminoquinolines.